AU2001296229A1 - Methods of using a human il-17-related polypeptide to treat disease - Google Patents

Methods of using a human il-17-related polypeptide to treat disease

Info

Publication number
AU2001296229A1
AU2001296229A1 AU2001296229A AU9622901A AU2001296229A1 AU 2001296229 A1 AU2001296229 A1 AU 2001296229A1 AU 2001296229 A AU2001296229 A AU 2001296229A AU 9622901 A AU9622901 A AU 9622901A AU 2001296229 A1 AU2001296229 A1 AU 2001296229A1
Authority
AU
Australia
Prior art keywords
human
methods
related polypeptide
treat disease
immunodeficiencies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296229A
Inventor
Andrew Lawrence Glasebrook
Ling Liu
Christy Michelle Newton
Jonathan Wendell Tetreault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001296229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001296229A1 publication Critical patent/AU2001296229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Methods are provided for the treatment or prevention of atherosclerosis, allergic autoimmune diseases, endothelial cell apoptosis, allograft vasculopathy, hypertension, congestive heart failure, ischemia/reperfusion injury, type 1 diabetes, inflammation, immunodeficiencies, cancers, and infectious diseases by administering a human IL-17 related polypeptide and/or an antibody recognizing an epitope thereof to a patient in need of such therapy.
AU2001296229A 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease Abandoned AU2001296229A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24017700P 2000-10-13 2000-10-13
US60/240,177 2000-10-13
US30993601P 2001-08-03 2001-08-03
US60/309,936 2001-08-03
PCT/US2001/027737 WO2002033083A2 (en) 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease

Publications (1)

Publication Number Publication Date
AU2001296229A1 true AU2001296229A1 (en) 2002-04-29

Family

ID=26933217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296229A Abandoned AU2001296229A1 (en) 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease

Country Status (7)

Country Link
US (1) US20060083713A1 (en)
EP (1) EP1326974B1 (en)
AT (1) ATE349523T1 (en)
AU (1) AU2001296229A1 (en)
DE (1) DE60125563T2 (en)
ES (1) ES2277947T3 (en)
WO (1) WO2002033083A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3112468A1 (en) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
PT1076703E (en) 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002033083A2 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
CN1688340A (en) * 2002-07-15 2005-10-26 韦思公司 Methods and compositions for modulating T helper (TH) cell development and function
MX341074B (en) 2003-07-08 2016-08-05 Genentech Inc Il-17 a/f heterologous polypeptides and therapeutic uses thereof.
AU2004275871A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
KR20100037047A (en) * 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 Methods of treating serotonin-mediated diseases and disorders
BRPI0908312A2 (en) 2008-05-05 2015-08-18 Novimmune Sa '' Isolated fully human monoclonal antibody, pharmaceutical composition, symptom-relieving method of a clinical indication, and method of relieving a symptom of an autoimmune disease, inflammatory disorder or cell proliferation disorder ''
US20120076754A1 (en) * 2009-05-20 2012-03-29 Ziad Mallat Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
US11135268B2 (en) * 2015-07-07 2021-10-05 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
CN106153923B (en) * 2016-06-21 2017-12-05 北京大学第一医院 Predict that glutamic-pyruvic transaminase is less than the system of the Patients with Chronic Hepatitis B inflammation degree of two times of normal upper limits
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1076703E (en) * 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
WO2000020593A1 (en) * 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
ES2380812T3 (en) * 1999-12-23 2012-05-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU784727B2 (en) * 2000-02-08 2006-06-01 Amgen, Inc. IL-17 like molecules and uses thereof
MXPA02012743A (en) * 2000-06-22 2003-04-25 Amgen Inc Il-17 molecules and uses thereof.
ATE365801T1 (en) * 2000-07-27 2007-07-15 Wyeth Corp MODULATION BY IL-TIF/INTERLEUKIN-21
WO2002033083A2 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease

Also Published As

Publication number Publication date
ES2277947T3 (en) 2007-08-01
DE60125563T2 (en) 2007-10-04
DE60125563D1 (en) 2007-02-08
ATE349523T1 (en) 2007-01-15
WO2002033083A3 (en) 2003-03-06
EP1326974A2 (en) 2003-07-16
US20060083713A1 (en) 2006-04-20
WO2002033083A2 (en) 2002-04-25
EP1326974B1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
AU2001296229A1 (en) Methods of using a human il-17-related polypeptide to treat disease
MXPA05013564A (en) Fusion proteins.
WO2003104273A3 (en) Therapeutic epitopes and uses thereof
EA200101250A1 (en) PREVENTION AND THERAPY OF AMYLOIDOGENIC DISEASE
MXPA05008406A (en) Phenylacetamides and their use as glucokinase modulators.
WO2004005326A3 (en) Tubulysin conjugates
FI956014A0 (en) Use of non- and decapeptides in the manufacture of a medicament for the treatment of AIDS
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
DK1151009T3 (en) Antimicrobial / endotoxin neutralizing polypeptide
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
CA2245123A1 (en) Use of rosaceae plant extract as a bradykinin antagonist
PT998287E (en) USES OF LEVOBUPIVACAINE
WO2003039591A3 (en) Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
ATE342716T1 (en) USE OF CARBOXY COMPOUNDS SUCH AS 2(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-ETHYLAMMONIUM CHLORIDE AS ANTI-INFLAMMATORY AGENTS
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
EA200401295A1 (en) STATIN THERAPY TO ENHANCE SUPPORT OF COGNITIVE FUNCTION
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
ATE293445T1 (en) PRODUCTION OF PURE STEREOISOMERS OF TRICYCLO-(5.2.1.0(2.6))-DEC-9-YL-XANTHOGENATE AND THEIR USE AS MEDICINAL PRODUCTS
ATE404519T1 (en) HYPERFORINE DERIVATIVES, THEIR USE AND PREPARATIONS CONTAINING THEM
DK0707477T3 (en) Use of Efaxoran and its derivatives in the manufacture of drugs intended to treat neurodegenerative diseases
WO2002026258A3 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions
WO2005046729A3 (en) Use of lipopeptides for activating t lymphocytes through the skin